Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

The spectrum of cluster headache: A case report of 4600 attacks.

Hagedorn A, Snoer A, Jensen R, Haddock B, Barloese M.

Cephalalgia. 2019 Mar 26:333102419833081. doi: 10.1177/0333102419833081. [Epub ahead of print]

PMID:
30913909
2.

Cluster headache beyond the pain phase: A prospective study of 500 attacks.

Snoer A, Lund N, Beske R, Hagedorn A, Jensen RH, Barloese M.

Neurology. 2018 Aug 28;91(9):e822-e831. doi: 10.1212/01.wnl.0000542491.92981.03. Epub 2018 Jul 27.

PMID:
30054443
3.

Change and Stability of Emotional Health of Rural Pennsylvania Youth During High School.

Wang D, Hagedorn AD, McLaughlin DK, Bray BC.

J Rural Health. 2018 Jun;34(3):322-332. doi: 10.1111/jrh.12296. Epub 2018 Feb 16.

4.

Biomechanical Responses of PMHS Subjected to Abdominal Seatbelt Loading.

Ramachandra R, Kang YS, Bolte JH 4th, Hagedorn A, Herriott R, Stammen JA, Moorhouse K.

Stapp Car Crash J. 2016 Nov;60:59-87.

PMID:
27871094
5.

4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms.

Michailidis E, Huber AD, Ryan EM, Ong YT, Leslie MD, Matzek KB, Singh K, Marchand B, Hagedorn AN, Kirby KA, Rohan LC, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.

J Biol Chem. 2014 Aug 29;289(35):24533-48. doi: 10.1074/jbc.M114.562694. Epub 2014 Jun 26.

6.

HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.

Smith JL, Izumi T, Borbet TC, Hagedorn AN, Pathak VK.

J Virol. 2014 Sep 1;88(17):9893-908. doi: 10.1128/JVI.01318-14. Epub 2014 Jun 18.

7.

Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.

Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG.

Antimicrob Agents Chemother. 2013 Dec;57(12):6254-64. doi: 10.1128/AAC.01703-13. Epub 2013 Oct 7.

8.

Biochemical mechanism of HIV-1 resistance to rilpivirine.

Singh K, Marchand B, Rai DK, Sharma B, Michailidis E, Ryan EM, Matzek KB, Leslie MD, Hagedorn AN, Li Z, Norden PR, Hachiya A, Parniak MA, Xu HT, Wainberg MA, Sarafianos SG.

J Biol Chem. 2012 Nov 2;287(45):38110-23. doi: 10.1074/jbc.M112.398180. Epub 2012 Sep 6.

9.

Estimation of multi-state life table functions and their variability from complex survey data using the SPACE Program.

Cai L, Hayward MD, Saito Y, Lubitz J, Hagedorn A, Crimmins E.

Demogr Res. 2010 Jan 26;22(6):129-158.

10.

Change in disability-free life expectancy for Americans 70-years-old and older.

Crimmins EM, Hayward MD, Hagedorn A, Saito Y, Brouard N.

Demography. 2009 Aug;46(3):627-46.

11.

A Comparison of Biological Risk Factors in Two Populations: The United States and Japan.

Crimmins EM, Vasunilashorn S, Kim JK, Hagedorn A, Saito Y.

Popul Dev Rev. 2008 Sep 5;34(3):457-482. No abstract available.

12.

A tale of two countries--the United States and Japan: are differences in health due to differences in overweight?

Reynolds SL, Hagedorn A, Yeom J, Saito Y, Yokoyama E, Crimmins EM.

J Epidemiol. 2008;18(6):280-90. Epub 2008 Dec 4.

13.

[External anal sphincter repair using the overlapping technique in patients with anal incontinence and concomitant pudendal nerve damage].

Gronewold M, Kroencke T, Hagedorn A, Tunn R, Gauruder-Burmester A.

Zentralbl Chir. 2008 Apr;133(2):129-34. doi: 10.1055/s-2008-1004734. German.

PMID:
18415899
14.

Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.

Harenberg J, Giese C, Hagedorn A, Traeger I, Fenyvesi T.

Semin Thromb Hemost. 2007 Jul;33(5):503-7.

PMID:
17629847
15.

Immunohistochemical study about the Flt-1/VEGFR1 expression in the gastrointestinal tract of mouse, rat, dog, swine and monkey.

Hagedorn A, Germann PG, Junker-Walker U, Tomovic A, Seewald W, Polkinghorne A, Pospischil A.

Exp Toxicol Pathol. 2005 Nov;57(2):149-59. Epub 2005 Jul 18.

PMID:
16325525
16.

Application of spectrofluorometry to the prediction of PHB concentrations in a fed-batch process.

Henneke D, Hagedorn A, Budman HM, Legge RL.

Bioprocess Biosyst Eng. 2005 Oct;27(6):359-364. doi: 10.1007/s00449-004-0375-z. Epub 2005 Nov 3.

PMID:
16047168
17.

Thrombosis of the ovarian and vaginal veins after caesarean section in a cow.

Bleul U, Hagedorn A, Kähn W.

Vet Rec. 2005 Jun 11;156(24):780-2. No abstract available.

PMID:
15951504
18.
19.

Screening for depression in chronic hemodialysis patients.

al-Hihi E, Awad A, Hagedorn A.

Mo Med. 2003 May-Jun;100(3):266-8.

PMID:
12847869
20.

Evaluation of spectrofluorometry as a tool for estimation in fed-batch fermentations.

Hagedorn A, Legge RL, Budman H.

Biotechnol Bioeng. 2003 Jul 5;83(1):104-11.

PMID:
12740937
21.

Life with and without disease: women experience more of both.

Crimmins EM, Kim JK, Hagedorn A.

J Women Aging. 2002;14(1-2):47-59.

PMID:
12537279
22.

(Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase.

Lampe JW, Chou YL, Hanna RG, Di Meo SV, Erhardt PW, Hagedorn AA 3rd, Ingebretsen WR, Cantor E.

J Med Chem. 1993 Apr 16;36(8):1041-7.

PMID:
8386770
23.

Cardiotonic agents. 7. Prodrug derivatives of 4-ethyl-1,3-dihydro- 5-[4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one.

Shaw KJ, Erhardt PW, Hagedorn AA 3rd, Pease CA, Ingebretsen WR, Wiggins JR.

J Med Chem. 1992 Apr 3;35(7):1267-72.

PMID:
1560439
24.

Cardiotonic agents. 5. Fragments from the heterocycle-phenyl-imidazole pharmacophore.

Erhardt PW, Hagedorn AA 3rd, Davey D, Pease CA, Venepalli BR, Griffin CW, Gomez RP, Wiggins JR, Ingebretsen WR, Pang D, et al.

J Med Chem. 1989 Jun;32(6):1173-6.

PMID:
2542552
25.

Cardiotonic agents. 3. A topographical model of the cardiac cAMP phosphodiesterase receptor.

Erhardt PW, Hagedorn AA 3rd, Sabio M.

Mol Pharmacol. 1988 Jan;33(1):1-13.

PMID:
2826995
26.

Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agents.

Hagedorn AA 3rd, Erhardt PW, Lumma WC Jr, Wohl RA, Cantor E, Chou YL, Ingebretsen WR, Lampe JW, Pang D, Pease CA, et al.

J Med Chem. 1987 Aug;30(8):1342-7.

PMID:
3039132
27.

Severe degenerative joint disease. Mild and moderately severe hemophilia A.

Gilchrist GS, Hagedorn AB, Stauffer RN.

JAMA. 1977 Nov 28;238(22):2383-5.

PMID:
578865
28.

Aspirin effects on human platelets: a scanning electron microscope study.

Lewis JC, Hagedorn AB.

Thromb Res. 1976 Dec;9(6):647-52. No abstract available.

PMID:
1006631
29.

Treatment of intravascular coagulation and fibrinolysis (ICF) syndromes.

Kazmier FJ, Bowie EJ, Hagedorn AB, Owen CA Jr.

Mayo Clin Proc. 1974 Sep;49(9):665-72. No abstract available.

PMID:
4416722
30.

Coagulation abnormalities in patients with inoperable lung cancer.

Hagedorn AB, Bowie EJ, Elveback LR, Owen CA Jr.

Mayo Clin Proc. 1974 Sep;49(9):647-53. No abstract available.

PMID:
4278033
31.

Leukoerythroblastosis. Diagnostic and prognostic significance.

Weick JK, Hagedorn AB, Linman JW.

Mayo Clin Proc. 1974 Feb;49(2):110-3. No abstract available.

PMID:
4544259
32.

Antihemophilic factor 8 in hemophilia. Use of concentrates to permit major surgery.

Mazza JJ, Bowie EJ, Hagedorn AB, Didisheim P, Taswell HF, Peterson LF, Owen CA Jr.

JAMA. 1970 Mar 16;211(11):1818-23. No abstract available.

PMID:
5467109
33.

The diagnosis and management of unusual bleeding in the surgical patient.

Bowie EJ, Owen CA Jr, Hagedorn AB.

Surg Clin North Am. 1969 Oct;49(5):1161-70. No abstract available.

PMID:
5307268
34.

[Acylaminoalkylbenzolsulfonylsemicarbazides as blood sugar decreasing substances].

Aumüller W, Fauland E, Hagedorn A, Heerdt R, Hübner M, Muth K, Weber H, Weyer R, Bänder A, Pfaff W, Schmidt FH, Stork H.

Arzneimittelforschung. 1969 Aug;19(8):Suppl:1350-4. German. No abstract available.

PMID:
5394453
35.

[Acylaminoalkylbenzolsulfonylaminopyrimidines as blood sugar decreasing substances].

Heerdt R, Hübner M, Fauland E, Hagedorn A, Weber H, Aumüller W, Muth K, Weyer R, Schmidt FH, Stork H.

Arzneimittelforschung. 1969 Aug;19(8):Suppl:1346-50. German. No abstract available.

PMID:
5394452
36.

Anemia in industry.

Hagedorn AB.

IMS Ind Med Surg. 1969 Mar;38(3):37-9. No abstract available.

PMID:
5254447
37.

Intravascular coagulation and hemangiomata.

Hagedorn AB, Thompson JH Jr, Bowie EJ, Owen CA Jr.

Thromb Diath Haemorrh Suppl. 1969;36:233-8. No abstract available.

PMID:
5375544
38.

Drugs and doctors. Problem in the production of certain behavioral disorders.

Hagedorn AB, Steinhilber RM.

Minn Med. 1967 Aug;50(8):1187-9. No abstract available.

PMID:
6058588
39.

Drug-induced behavior disorders.

Steinhilber RM, Hagedorn AB.

GP. 1967 May;35(5):115-8. No abstract available.

PMID:
6046509
40.

What's new in hematology?

Hagedorn AB.

Minn Med. 1966 Nov;49(11):1757-61. No abstract available.

PMID:
5979489
41.

Anemia in temporal arteritis.

Whitaker JJ, Hagedorn AB, Pease GL.

Postgrad Med. 1966 Jul;40(1):35-9. No abstract available.

PMID:
5945686
42.

Erythermalgia. A clue to the early diagnosis of myeloproliferative disorders.

Alarcon-Segovia D, Babb RR, Fairbairn JF 2nd, Hagedorn AB.

Arch Intern Med. 1966 Apr;117(4):511-5. No abstract available.

PMID:
5906643
43.

EVALUATION OF ANTIHYPERTENSIVE THERAPY. II. DOUBLE-BLIND CONTROLLED EVALUATION OF MEBUTAMATE.

BAYRD ED, HAGEDORN AB, MCGUCKIN WF.

JAMA. 1965 Aug 30;193:727-9. No abstract available.

PMID:
14328472
44.

MACROGLOBULINEMIA, ITS RECOGNITION AND TREATMENT.

BAYRD ED, HAGEDORN AB, MCGUCKIN WF.

JAMA. 1965 Aug 30;193:724-6. No abstract available.

PMID:
14328471
45.

PURPURA. THE ALLERGIC ASPECTS.

BOWIE EJ, HAGEDORN AB.

Minn Med. 1964 Nov;47:1329-32. No abstract available.

PMID:
14243346
46.

AN ELECTROPHORETIC STUDY OF SERUM PROTEIN-BOUND CARBOHYDRATE IN DYSPROTEINEMIA.

EVENSON DJ, MCGUCKIN WF, MCKENZIE BF, HAGEDORN AB.

Clin Chem. 1964 Sep;10:824-37. No abstract available.

47.

TOTAL IRON-BINDING CAPACITY IN NORMAL PREGNANCY.

MALKASIAN GD Jr, TAUXE WN, HAGEDORN AB.

J Nucl Med. 1964 Apr;5:243-50. No abstract available.

48.

Evaluation of the anemia of rheumatoid arthritis.

ROBERTS FD, HAGEDORN AB, SLOCUMB CH, OWEN CA.

Blood. 1963 Apr;21:470-8. No abstract available.

49.

Anemia not responding to iron therapy.

HAGEDORN AB.

Minn Med. 1962 Apr;45:388-90. No abstract available.

PMID:
13903580
50.

Anemia and other hematologic abnormalities as manifestations of malignant disease.

HAGEDORN AB.

Ill Med J. 1962 Apr;121:365-8. No abstract available.

PMID:
13903579

Supplemental Content

Loading ...
Support Center